Palmitoyl tetrapeptide-7 (Rigin)

Also known as: Pal-GQPR

Not FDA-approved

Last verified: October 30, 2026

At a glance

FDA approval Not FDA-approved No record in Drugs@FDA
Randomized controlled trials 1 of 6 publications on PubMed
Registered clinical trials 1 0 active
Adverse event reports 0 0 classified as serious
  • Palmitoyl tetrapeptide-7 (Rigin) is not an FDA-approved drug: Drugs@FDA has no record of it.
  • PubMed lists 6 publications mentioning it, including 1 randomized controlled trial and 0 animal-only studies.
  • ClinicalTrials.gov lists 1 registered study testing it (0 active).
  • FDA’s adverse event system (FAERS) has no reports mentioning it.

Research topics

  • Collagen 2
  • Administration, Topical 1
  • Aging 1
  • Angiogenesis 1
  • Cell Proliferation 1
  • Cell Survival 1
  • Chitosan 1
  • Decorin 1
  • Dermis 1
  • Diabetes Mellitus, Experimental 1

Most frequent MeSH subject headings in the latest PubMed records (English, as indexed).

Regulatory status

Drugs@FDA applications

No application found in Drugs@FDA, FDA's database of approved drugs.

Source: Drugs@FDA (openFDA) · verified October 30, 2026 · API query

FDA compounding safety list

Not on FDA's list of bulk drug substances that may present significant safety risks in compounding.

Source: FDA.gov — Category 2 bulk drug substances · verified October 30, 2026

Removal of a substance from a regulatory list does not mean it has been approved. A "research use only" label does not make a product safe or legal for human use.

Scientific publications

  • All publications 6
  • Human (MeSH) 3
  • Animal only 0
  • Clinical trials 1
  • Randomized controlled trials 1
  • Systematic reviews & meta-analyses 0
  • Case reports 0
  • Retracted 0

Counts are PubMed records that mention the peptide in the title or abstract. Categories overlap, and a mention is not the same as testing the peptide as a treatment. Each number opens the exact PubMed search. Effects seen in laboratory or animal studies may not occur in humans. A registered clinical trial does not show that a substance is effective or safe.

Latest publications

Source: PubMed (NCBI) · verified October 30, 2026

Clinical trials

Registered
1
Active
0
With posted results
0

Conditions studied

  • Cutis Laxa Facialis 1
  • Xeroderma 1
Study Status Phase Start
Trial Assessing the Impact on Facial Skin Quality, Hydration, and Skin Barrier of Three (3) Hydrafacial Treatments in Adults of All Skin Types.
NCT05932732 Austin Institute for Clinical Research
Completed Phase 4 November 20, 2023

All 1 study on ClinicalTrials.gov ↗

Source: ClinicalTrials.gov · verified October 30, 2026

Adverse event reports

No FAERS reports mention this peptide.

Source: FDA FAERS · verified October 30, 2026 · API query

FDA prescribing information

Official US prescribing information. Dosing sections are intentionally not shown.

Source: DailyMed / openFDA

Change history

No changes since monitoring began on October 30, 2026.